• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Corrigendum to "FUTURE-2: Results from an open-label, long-term safety and tolerability extension study using the pediatric FormUlation of bosenTan in pUlmonary arterial hypeRtEnsion" [Int. J. Cardiol. 202 (2016) 52-58].

作者信息

Berger Rolf M F, Haworth Sheila G, Bonnet Damien, Dulac Yves, Fraisse Alain, Galiè Nazzareno, Ivy D Dunbar, Jaïs Xavier, Miera Oliver, Rosenzweig Erika B, Efficace Michela, Kusic-Pajic Andjela, Beghetti Maurice

机构信息

Center for Congenital Heart Diseases, Department of Paediatric Cardiology, Beatrix Children's Hospital, University Medical Centre, Groningen, The Netherlands.

Institute of Child Health, University College, London, UK.

出版信息

Int J Cardiol. 2016 Nov 15;223:1072-1073. doi: 10.1016/j.ijcard.2016.08.333. Epub 2016 Aug 24.

DOI:10.1016/j.ijcard.2016.08.333
PMID:27623401
Abstract
摘要

相似文献

1
Corrigendum to "FUTURE-2: Results from an open-label, long-term safety and tolerability extension study using the pediatric FormUlation of bosenTan in pUlmonary arterial hypeRtEnsion" [Int. J. Cardiol. 202 (2016) 52-58].《“FUTURE-2：使用波生坦儿科剂型治疗肺动脉高压的开放标签、长期安全性和耐受性扩展研究结果”勘误》[《国际心脏病学杂志》202卷（2016年）第52 - 58页]
Int J Cardiol. 2016 Nov 15;223:1072-1073. doi: 10.1016/j.ijcard.2016.08.333. Epub 2016 Aug 24.
2
FUTURE-2: Results from an open-label, long-term safety and tolerability extension study using the pediatric FormUlation of bosenTan in pUlmonary arterial hypeRtEnsion.FUTURE-2：一项使用波生坦儿科制剂治疗肺动脉高压的开放标签长期安全性和耐受性扩展研究的结果
Int J Cardiol. 2016 Jan 1;202:52-8. doi: 10.1016/j.ijcard.2015.08.080. Epub 2015 Aug 9.
3
Long-term trial of bosentan monotherapy for pulmonary arterial hypertension in Japanese patients.波生坦单药治疗日本肺动脉高压患者的长期试验。
Curr Med Res Opin. 2007 Feb;23(2):395-400. doi: 10.1185/030079906X167390.
4
Relative bioavailability of a newly developed pediatric formulation of bosentan vs. the adult formulation.波生坦新开发的儿科制剂与成人制剂的相对生物利用度。
Int J Clin Pharmacol Ther. 2013 Jun;51(6):529-36. doi: 10.5414/CP201806.
5
Long-term safety, tolerability and efficacy of bosentan in adults with pulmonary arterial hypertension associated with congenital heart disease.波生坦用于患有与先天性心脏病相关的肺动脉高压的成人患者的长期安全性、耐受性及疗效
Heart. 2007 Aug;93(8):974-6. doi: 10.1136/hrt.2006.089185.
6
Bosentan treatment for pulmonary arterial hypertension related to connective tissue disease: a subgroup analysis of the pivotal clinical trials and their open-label extensions.波生坦治疗与结缔组织病相关的肺动脉高压：关键临床试验及其开放标签扩展研究的亚组分析
Ann Rheum Dis. 2006 Oct;65(10):1336-40. doi: 10.1136/ard.2005.048967. Epub 2006 Jun 22.
7
Long-term results from the EARLY study of bosentan in WHO functional class II pulmonary arterial hypertension patients.波生坦用于WHO功能分级II级肺动脉高压患者的EARLY研究的长期结果。
Int J Cardiol. 2014 Mar 15;172(2):332-9. doi: 10.1016/j.ijcard.2013.12.179. Epub 2014 Jan 9.
8
Predictors of long-term outcomes in patients treated with riociguat for pulmonary arterial hypertension: data from the PATENT-2 open-label, randomised, long-term extension trial.利奥西呱治疗肺动脉高压患者的长期结局预测因素：来自 PATENT-2 开放性、随机、长期扩展试验的数据。
Lancet Respir Med. 2016 May;4(5):361-71. doi: 10.1016/S2213-2600(16)30019-4. Epub 2016 Apr 8.
9
Clinical efficacy and safety of switch from bosentan to macitentan in children and young adults with pulmonary arterial hypertension.在儿童和年轻成人肺动脉高压患者中从波生坦转换为马昔腾坦的临床疗效与安全性。
Cardiol Young. 2018 Apr;28(4):542-547. doi: 10.1017/S1047951117002542. Epub 2017 Dec 13.
10
Safety and tolerability evaluation of oral bosentan in adult congenital heart disease associated pulmonary arterial hypertension: a systematic review and meta-analysis.口服波生坦治疗成人先天性心脏病相关肺动脉高压的安全性和耐受性评估：一项系统评价和荟萃分析。
Eur Rev Med Pharmacol Sci. 2014;18(5):638-45.